Navigation Links
Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function
Date:3/12/2009

PHILADELPHIA, March 12 /PRNewswire/ -- On the occasion of World Kidney Day, Kibow Biotech, Inc. is pleased to announce that it will soon be introducing a breakthrough probiotic formulation as a scientifically formulated and clinically tested dietary supplement product, which, when taken regularly as instructed, could help maintain healthy kidney function.

Kibow Biotech, Inc. is an 11 year-old, Philadelphia suburban-based biotech company with unique and pioneering probiotic-based dietary supplements for supporting renal health.

The Company's lead product, Kibow Biotics(R) has its own self-acclaimed US FDA GRAS status. GRAS is an acronym for Generally Recognized As Safe and means that the substance is generally recognized, among qualified scientific and medical experts, as having been adequately shown to be safe under the conditions of its intended use.

Although Kibow is currently conducting a pilot scale human clinical study of this formulation in five different countries, Kibow Biotics(R) will be introduced as a dietary supplement rather than a drug to US consumers to help maintain healthy kidney function.

Dr. Natarajan Ranganathan, Interim CEO and VP Research and Development, stated, "By offering an affordable, readily available and easy-to-administer dietary supplement product in the USA, Kibow aims to make Kibow Biotics accessible to all those who suffer from kidney problems in other countries worldwide according to individual countries' governmental rules and regulatory authorities."

Kibow Biotics will be available online (http://www.kibow.com) in the USA starting on April 3, 2009.

For more information, visit http://www.kibow.com

Forward-looking statements

This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Kibow Biotics(R), for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Kibow Biotics will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Kibow Biotics may not prove to be safe or show evidence of clinical activity in the current limited human trials or that data from patients enrolled in the study may not be useful or conclusive or sufficient to guide future development of Kibow Biotics. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop dietary supplements using the technologies of the Company, risks associated with completing clinical trials of product candidates, the possibility that clinical testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

    For further information, contact:

    Dr. Natarajan Ranganathan
    CEO and VP Research and Development
    1 (610) 353 5130

http://www.kibow.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Kibow Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... ... to announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton ... one of the founding commercial leaders responsible for the commercialization of multiple orphan ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group and ... Symposium as other research and development initiatives for potential stem cell protocol management for ... Stem Cells Group executives began meeting to establish a working agenda and foster initiatives ...
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office ... as one of three finalists for the European Inventor Award 2016 in the category ... will be announced at a ceremony in Lisbon on June 9th. , The human ...
(Date:4/26/2016)... ... 26, 2016 , ... Seattle based non-profit, The Institute for ... Corporation. The grant will be used to further the scientific research goals of ... http://www.ivsci.org , In accounting the grant to the IVS, Mr. Glenn ...
Breaking Biology Technology:
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/18/2016)... --> --> Competitive Landscape Analysis ... Physical infrastructure and Perimeter Surveillance & Detection Systems ... and the continuing migration crisis in the Middle ... led visiongain to publish this unique report, which is crucial ... & security companies in the border security market and the ...
(Date:3/14/2016)... 14, 2016 http://www.apimages.com ) ... --> - Renvoi : image disponible via AP ... --> --> DERMALOG, le leader ... nouveaux lecteurs d,empreintes digitales pour l,enregistrement des réfugiés ... utilisé pour produire des cartes d,identité aux réfugiés. ...
Breaking Biology News(10 mins):